After disappointments, Alzheimer's researchers seek out new paths: Biomarkers and combination therapies may lead to disease-modifying treatments, experts say

P and T

Volumn 39, Issue 5, 2014, Pages

  Worley, Susan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; CHOLESTEROL; CRENEZUMAB; DONEPEZIL; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GALANTAMINE; GANTENERUMAB; INSULIN; MEMANTINE; PIOGLITAZONE; PLACEBO; RIVASTIGMINE; SOLANEZUMAB; TACRINE;

ALZHEIMER DISEASE; ARTICLE; HUMAN; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY;

EID: 84901466531     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):322-333.
2. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):311-321.
3. Vellas B, Black R, AN1792 (QS-21)-251 Study Team, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6(2):144-151.
4. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3(111):111cm33.
5. Arnold SE, Louneva N, Cao K, et al. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol Aging 2013;34(1):157-168.
6. Negash S, Wilson RS, Leurgans SE, et al. Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition. Curr Alzheimer Res 2013;10(8):844-851.
7. Wirth M, Villeneuve S, Haase CM, et al. Associations between Alz heimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013;70(12):1512-1519.
8. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12(4):357-367.
9. Sperling RA, Rentz DM, Johnson KA, et al. Stopping AD before symptoms begin? Sci Transl Med 2014;6(228):228fs13.
10. Doraiswamy PM, Sperling RA, Johnson K, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular Psychiatry [published online ahead of print March 11, 2014] doi:10.1038/mp.2014.9.
11. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306-319.
12. Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol 2013;9:621-648.
13. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79(6):1094-1108.
14. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013:9(6):666-676.
15. Snyder HM, Carrillo MC, Grodstein F, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014;10(1):109-114.
16. Mapstone M, et al Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014; doi:10.1038/ nm.3466.
17. Kozauer N, Katz R. Regulatory innovation and drug devel opment for early-stage Alzheimer's disease. N Engl J Med 2013;368(13):1169-1171.
18. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804.
19. Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer's Res Therapy 2013;5(5):48.
20. National Institutes of Health. A study of crenezumab versus pla cebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer disease, including a placebo-treated noncarrier cohort. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01998841. Accessed April 14, 2014.
21. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11(12):1048-1056.
22. National Institutes of Health. Biomarker qualification for risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and safety and efficacy evaluation of pioglitazone in delaying its onset. Available at: http://clinicaltrials.gov/show/NCT01931566. Accessed April 14, 2014.
23. National Institutes of Health. The study of nasal insulin in the fight against forgetfulness (SNIFF). Available at: http://clinicaltrials.gov/show/NCT01767909. Accessed April 14, 2014.
24. Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed April 2, 2014.
25. Razadyne, prescribing information. Titusville, New Jersey; Janssen Pharmaceuticals; 2013.
26. Exelon, prescribing information. East Hanover, New Jersey; No vartis Pharmaceuticals; 2013.
27. Aricept, prescribing information. Woodcliff Lake, New Jersey; Eisia Inc.; 2013.
28. Namenda, prescribing information. St. Louis, Missouri; Forest Laboratories; 2013.